Published in JAMA · View the paper (DOI)
In a groundbreaking 68-week study, semaglutide combined with intensive behavioral therapy resulted in an average weight loss of 16% for participants, exceeding one-third who lost 20% or more of their baseline weight. The treatment also showed significant improvements in cardiometabolic risk factors and marked metabolic benefits.
Coverage from 2 institutions